Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01497184 | Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood | completed | Phase 1 | 95 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05386355 | Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool(MoVeUP) | completed | N/A | 1,934 | IDeA States Pediatric Clinical Trials NetworkNETWORK | 1 | Mar 11, 2025 | clinicaltrials |
| NCT00619879 | Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies | completed | — | 81 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT00719888 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | completed | Phase 2 | 135 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06865352 | Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 15 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT02834390 | Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 | 7 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT02396134 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02484430 | Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04126681 | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | completed | Phase 2 | 144 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT01895842 | Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04312841 | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06488456 | Psychometric Properties of the Therapy-Related Symptom Checklist-Children | completed | — | 300 | Ege UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT02828358 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 4 | Feb 27, 2025 | clinicaltrials |
| NCT02038777 | A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | completed | Phase 1 | 48 | PfizerINDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04896580 | IIT2020-20-SHIRAZIP-WALK: Nature Walks | completed | N/A | 20 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05131815 | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors | completed | N/A | 8 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04242849 | IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up | completed | — | 354 | Josep Carreras Leukaemia Research InstituteOTHER | 0 | Feb 21, 2025 | clinicaltrials |
| NCT05826288 | Oncology Care at Home for BMT and CAR-T | completed | N/A | 11 | University of Colorado, DenverOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03839446 | Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy | completed | Phase 2 | 16 | Robert Redner, MDOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT00390793 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | completed | Phase 2 | 107 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03654716 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04372433 | IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML | completed | Phase 1 | 67 | Immune-Onc TherapeuticsINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05030675 | Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03088878 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 95 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03114553 | Family History in a Singaporean Healthy Population | completed | — | 1,000 | Duke UniversityOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT05587582 | Behavioral Parenting Skills As A Novel Target for Improving Pediatric Medication Adherence | completed | — | 51 | Roswell Park Cancer InstituteOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT00179868 | C-Reactive Protein as a Predictor of Stem Cell Transplant Complications | completed | — | 70 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT03751709 | Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL | completed | Phase 1 | 22 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT00179829 | WT1 for the Detection of Minimal Residual Disease | completed | Phase 2 / Phase 3 | 50 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT05992246 | The Ratio of Femoral Vein Diameter to Femoral Artery Diameter to Predict Fluid Responsiveness in Children | completed | — | 85 | Tanta UniversityOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03027102 | Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia | completed | Phase 1 | 7 | University Health Network, TorontoOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03476655 | Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India | completed | — | 40 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT05034354 | Virtual Remote Physiological Monitoring Program of Children With Heart Disease | completed | N/A | 23 | University of AlbertaOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT02388048 | Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia | completed | Phase 2 | 19 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06790680 | GITMO AML/MDS-Relapse Registry Study | completed | — | 859 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT01690624 | BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05775406 | Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | completed | Phase 1 | 52 | Kymera Therapeutics, Inc.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT01541800 | Circulating microRNAs as Disease Markers in Pediatric Cancers | completed | — | 20 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04689204 | A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies | completed | Early Phase 1 | 3 | He HuangOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT01261312 | SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 414 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT03367299 | Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia(LAL2317) | completed | Phase 2 | 149 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06782854 | Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy | completed | — | 102 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783738 | Physical Activity in Acute Lymphoblastic Leukemia (ALL)(ALL) | completed | N/A | 21 | University of California, IrvineOTHER | 0 | Jan 20, 2025 | clinicaltrials |
| NCT02997202 | A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 356 | Astellas Pharma Global Development, Inc.INDUSTRY | 16 | Jan 17, 2025 | clinicaltrials |
| NCT03870633 | Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma | completed | — | 521 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT03092674 | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 / Phase 3 | 76 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2025 | clinicaltrials |
| NCT04716075 | Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)(ACALLO) | completed | Phase 2 | 29 | Polish Lymphoma Research GroupNETWORK | 1 | Jan 16, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 13, 2025source: clinicaltrials